From Wikipedia, the free encyclopedia
|Chemical and physical data|
|Molar mass||144.6 kg/mol|
|(what is this?)|
Sirukumab (INN, USAN) (developmental code name CNTO-136) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis. It acts against the proinflammatory cytokine Interleukin 6 (IL-6).
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Sirukumab" (PDF). American Medical Association.
- Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
- A Study of the Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy, clinicaltrials.gov
- Glaxo says top-line results positive in late-stage study of sirukumab in rheumatoid arthritis. Dec 2015
- IL-6 in RA: What Predicts Non-Progression? - High-risk patients showed most benefit with sirukumab. Jan 2017
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|